AgingResearch.NewsJoin free

B cell intracellular TNF-α

Biomarker

1 paper studies it1 finding

  • Human trial1

Interventions

1

Allogeneic mesenchymal stem cells

downin humans1

1 study

  1. Allogeneic mesenchymal stem cells decrease B cell intracellular TNF-α in humans (p < .0001 and p = .002; p = .003 and p = .039 versus placebo).

    “B cell intracellular TNF-α improved in both the 100M- (p < .0001) and 200M-groups (p = .002) as well as between groups compared to placebo (p = .003 and p = .039, respectively).”

    Human trialaging frailty100 or 200 million cells6 months postinfusion

    Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on Allogeneic mesenchymal stem cells

Latest

Related